Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues

Journal of Virological Methods

Volumn 88, Issue 2, 2000, Pages 117-124

  Clarke, J R ^a   Kaye, S ^b   Babiker, Abael G ^c   Hooker, Malmolm H ^c   Tedder, R ^b   Weber, J N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Med Res Cncl Clinical Trials Unit   (United Kingdom)

Author keywords

HIV 1 reverse transcriptase gene; Line probe assay (LiPA); Point mutation assay (PMA)

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; ASSAY; CODON; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA SEQUENCE; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SEQUENCE ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033839410     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(00)00173-7     Document Type: Article

References (16)

1. Brun-Vezinet, F., Boucher, C.A.B., Loveday, C., Descamps, D., Fouveau, V., Izopet, J., Jeffries, D., Kaye, S., Krzyzanowski, C., Nunn, A., Schuurman, R., Seigneurin, J.-M., Tamalet, C., Tedder, R., Weber, J.N., Weverling, G.-J. and the DELTA Virology Working Group and Co-ordinating Committee, 1997. HIV-1 viral load, phenotype and resistance in a subset of naive participants from the DELTA trial. Lancet 350, 983-990.
2. D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, A.J., Kuritzkes, D.R., De Gruttola, V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C.S., Kahn, J.O., Richman, D.D. for the AIDS Clinical Trial Group Protocol 116B/117 Team, 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122, 401-408.
3. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 33:1995;200-239.
4. Furman P.A., Fyfe M.H., St. Clair K., Weinhold K., Rideout J.L., Freeman J.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3-azido-3-deoxythymidine and selective interaction of the 5-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83:1986;8333-8337.
5. Hirsch M.S., Conway B., D'Aquila R.T., Johnson V.A., Brun-Vezinet F., Clotet B., Demeter L.M., Hammer S.M., Jacobsen D.M., Kuritzkes D.R., loveday C., Mellors J.W., Vella S., Richman D.D. Antiretroviral drug resistance testing in adults with HIV infection. J. Am. Med. Assoc. 279:1998;1984-1991.
6. Holodniy M., Katzenstein D., Mole L., Winters M., Merigan T. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium inducing phenotype. J. Infect. Dis. 174:1996;854-857.
7. Japour, A.J., Welles, S., D'Aquila, R.T., Johnson, V.A., Richman, D.D., Coombs, R.W., Reichelderfer, P.S., Kahn, J.O., Crumpacker, C.S., Kuritzkes, D.R. for the AIDS Clinical Trials Group 116B/117, 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171, 1172-1179.
8. Kaye S., Loveday C., Tedder R.S. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J. Med. Virol. 37:1992;241-246.
9. Kellam P., Boucher C.A.B., Larder B. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc. Natl. Acad. Sci. USA. 89:1992;1934-1938.
10. Merigan T., Hirsch R.L., Fisher A.C., Meyerson L.A., Goldstein G., Winters M.A. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS. 10:1996;159-165.
11. Moyle G. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J. Antimicrob. Chemother. 40:1997;765-777.
12. A randomised trial comparing four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial. AIDS. 13:1999;2209-2217.
13. Schinazi R.F. Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspect. Drug Dev. Design. 1:1993;151-180.
14. Shafer, R.W., Iversen, A.K., Winters, M.A., Aguiniga, E., Katzenstein, D.A., Merigan, T.C., and the AIDS Clinical Trials Group 143 Team, 1995. Drug resistance and heterogeneous long-term responses of human immunodeficiency virus type1 infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172, 70-78.
15. Stuyver L., Wyseur A., Rombout A., Louwagie J., Scarcez T., Verhofstede C., Rimland D., Schinazi R.F., Rossau R. Line probe assay for rapid detection of drug selected mutations in the human immunodeficiency virus reverse transcriptase gene. Antimicrob. Agents Chemother. 41:1997;284-291.
16. Vandamme A.M., Vaerenbergh K.V., DeClercq E. Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem. Chemother. 8:1998;187-203.